Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery

Ripretinib is a tyrosine kinase inhibitor that was approved by the United States FDA in 2020 for treatment of advanced gastrointestinal stromal tumor (GIST) in patients who received prior treatment with three or more tyrosine kinase inhibitors. In this case report, we show the durable clinical benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouda, Mohamed A., Janku, Filip, Somaiah, Neeta, Hunt, Kelly K., Yedururi, Sireesha, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511119/
https://www.ncbi.nlm.nih.gov/pubmed/37736254
http://dx.doi.org/10.18632/oncoscience.586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511119/
https://www.ncbi.nlm.nih.gov/pubmed/37736254
http://dx.doi.org/10.18632/oncoscience.586

Ejemplares similares